I’m so glad to hear this. I posted back in 2027/
Post# of 148188
(Total Views: 620)
Posted On: 03/12/2024 6:44:24 PM
I’m so glad to hear this. I posted back in 2027/18 that I was excited about host versus graft disease being studied using Leronlimab.
My reasoning was simple. GvHD is a condition where the immune rejects “foreign proteins” in the body bc it thinks it’s a virus etc. So, at the time of the study launch, they were looking at bone marrow transplants and the quite possible rejections or the advent of GvHD. Small market for these things. Large expense to study.
Well guess what is responsible for the several cured HIV patients, London partient etc? Bone marrow transplants with CCR5 absent spinal fluid due to delta allele hereditary knockout. At one point we thought by occupancy of CCR5 receptors we could replicate that, but nobody can cure HIV via bone marrow transplants at scale.
And this very special nugget. The reason Jonah Sacha’s AAV en vitro work (amazing) might quite be successful in curing HIV is that by occupying the CCR5 receptor completely and with ongoing receptor occupancy, it may replicate the bone marrow cures. But at scale. A simple solution to a complex (hard earned) scientific discovery.
Others have disagreed with me in years past, that GvHD was very important for us. So this report from you Enjay very much pleases me.
GvHD was a small market and might not have been worth investing money in. But for the implications it seems to me to be a reasonable exploration.
Thx, GLTA.
My reasoning was simple. GvHD is a condition where the immune rejects “foreign proteins” in the body bc it thinks it’s a virus etc. So, at the time of the study launch, they were looking at bone marrow transplants and the quite possible rejections or the advent of GvHD. Small market for these things. Large expense to study.
Well guess what is responsible for the several cured HIV patients, London partient etc? Bone marrow transplants with CCR5 absent spinal fluid due to delta allele hereditary knockout. At one point we thought by occupancy of CCR5 receptors we could replicate that, but nobody can cure HIV via bone marrow transplants at scale.
And this very special nugget. The reason Jonah Sacha’s AAV en vitro work (amazing) might quite be successful in curing HIV is that by occupying the CCR5 receptor completely and with ongoing receptor occupancy, it may replicate the bone marrow cures. But at scale. A simple solution to a complex (hard earned) scientific discovery.
Others have disagreed with me in years past, that GvHD was very important for us. So this report from you Enjay very much pleases me.
GvHD was a small market and might not have been worth investing money in. But for the implications it seems to me to be a reasonable exploration.
Thx, GLTA.
(8)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼